Connect with us
MindBio says its studies are funded into 2025. MindBio Therapeutics Corp. (CSE:MBIO) reported durability data from its Phase 2A clinical trials in depressed patients testing MB22001,...
Canadian psychedelics firm MindBio Therapeutics Corp. (CSE: MBIO) on Friday released durability results from its Phase 2A trial for its patented take-home microdose version of lysergic...
A newly published study from researchers at New York University found that individuals dealing with a stutter derived some benefit from substances such as psilocybin, the...
As it turns out, your marital status could affect the extent to which psychedelics can lower your stress levels. And it appears that single folk may...
As cannabis and psychedelics continue to experience a modern-day renaissance, with increased education and access to information surrounding their use and benefits, we’re collectively crafting new...
